ADC Therapeutics SA Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline
Reuters
Oct 13
<a href="https://laohu8.com/S/ADCT">ADC Therapeutics SA</a> Publishes Corporate Presentation Highlighting ZYNLONTA® Expansion and Advancements in ADC Pipeline
ADC Therapeutics SA has released a new corporate presentation highlighting its commercial-stage activities in the field of antibody-drug conjugates (ADCs). The company is focused on expanding its FDA-approved therapy ZYNLONTA® for relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), with ongoing research into its use in earlier lines of therapy and additional indications, including combination regimens and treatment of indolent lymphomas. The presentation also outlines progress on a next-generation, PSMA-targeting ADC candidate that is advancing towards investigational new drug (IND) enabling activities. Internal market research is referenced to show ZYNLONTA's current position within U.S. treatment options for r/r DLBCL and potential for market share growth through combination therapies. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.